Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 128.54
LCI's Cash to Debt is ranked higher than
85% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. LCI: 128.54 )
LCI' s 10-Year Cash to Debt Range
Min: 0   Max: 128.54
Current: 128.54

0
128.54
Equity to Asset 0.86
LCI's Equity to Asset is ranked higher than
92% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. LCI: 0.86 )
LCI' s 10-Year Equity to Asset Range
Min: -1.05   Max: 0.86
Current: 0.86

-1.05
0.86
Interest Coverage 677.61
LCI's Interest Coverage is ranked higher than
73% of the 484 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.05 vs. LCI: 677.61 )
LCI' s 10-Year Interest Coverage Range
Min: 1.15   Max: 677.61
Current: 677.61

1.15
677.61
F-Score: 7
Z-Score: 21.10
M-Score: -1.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 32.18
LCI's Operating margin (%) is ranked higher than
97% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.55 vs. LCI: 32.18 )
LCI' s 10-Year Operating margin (%) Range
Min: -119.46   Max: 46.27
Current: 32.18

-119.46
46.27
Net-margin (%) 20.86
LCI's Net-margin (%) is ranked higher than
95% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.99 vs. LCI: 20.86 )
LCI' s 10-Year Net-margin (%) Range
Min: -73   Max: 28.64
Current: 20.86

-73
28.64
ROE (%) 26.62
LCI's ROE (%) is ranked higher than
95% of the 796 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. LCI: 26.62 )
LCI' s 10-Year ROE (%) Range
Min: -38.23   Max: 117.18
Current: 26.62

-38.23
117.18
ROA (%) 22.58
LCI's ROA (%) is ranked higher than
97% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. LCI: 22.58 )
LCI' s 10-Year ROA (%) Range
Min: -28.9   Max: 50.98
Current: 22.58

-28.9
50.98
ROC (Joel Greenblatt) (%) 79.81
LCI's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.22 vs. LCI: 79.81 )
LCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -162.82   Max: 107.31
Current: 79.81

-162.82
107.31
Revenue Growth (%) 24.90
LCI's Revenue Growth (%) is ranked higher than
89% of the 670 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. LCI: 24.90 )
LCI' s 10-Year Revenue Growth (%) Range
Min: -3.6   Max: 48.4
Current: 24.9

-3.6
48.4
EBITDA Growth (%) 152.30
LCI's EBITDA Growth (%) is ranked higher than
99% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. LCI: 152.30 )
LCI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 152.3
Current: 152.3

0
152.3
» LCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

LCI Guru Trades in Q3 2013

Steven Cohen 16,217 sh (New)
Jim Simons 198,300 sh (+7.31%)
» More
Q4 2013

LCI Guru Trades in Q4 2013

Paul Tudor Jones 7,818 sh (New)
Jim Simons 188,400 sh (-4.99%)
Steven Cohen 7,348 sh (-54.69%)
» More
Q1 2014

LCI Guru Trades in Q1 2014

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 111,800 sh (-40.66%)
» More
Q2 2014

LCI Guru Trades in Q2 2014

Chuck Royce 338,400 sh (New)
Joel Greenblatt 35,709 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with LCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy0.02%$29.62 - $49.76 $ 40.243%35709
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.40
LCI's P/E(ttm) is ranked higher than
85% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.90 vs. LCI: 26.40 )
LCI' s 10-Year P/E(ttm) Range
Min: 13.82   Max: 185.79
Current: 26.4

13.82
185.79
P/B 4.86
LCI's P/B is ranked higher than
63% of the 828 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. LCI: 4.86 )
LCI' s 10-Year P/B Range
Min: 0.61   Max: 14.82
Current: 4.86

0.61
14.82
P/S 5.18
LCI's P/S is ranked higher than
65% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. LCI: 5.18 )
LCI' s 10-Year P/S Range
Min: 0.49   Max: 8.05
Current: 5.18

0.49
8.05
PFCF 89.42
LCI's PFCF is ranked higher than
83% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 89.42 )
LCI' s 10-Year PFCF Range
Min: 3.21   Max: 342.5
Current: 89.42

3.21
342.5
EV-to-EBIT 14.89
LCI's EV-to-EBIT is ranked higher than
89% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.14 vs. LCI: 14.89 )
LCI' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 687.5
Current: 14.89

6.9
687.5
PEG 0.48
LCI's PEG is ranked higher than
98% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 0.48 )
LCI' s 10-Year PEG Range
Min: 0.2   Max: 77.25
Current: 0.48

0.2
77.25
Shiller P/E 83.61
LCI's Shiller P/E is ranked higher than
76% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 121.61 vs. LCI: 83.61 )
LCI' s 10-Year Shiller P/E Range
Min: 21.37   Max: 358
Current: 83.61

21.37
358
Current Ratio 5.65
LCI's Current Ratio is ranked lower than
80% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. LCI: 5.65 )
LCI' s 10-Year Current Ratio Range
Min: 0.96   Max: 5.65
Current: 5.65

0.96
5.65
Quick Ratio 4.70
LCI's Quick Ratio is ranked lower than
80% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. LCI: 4.70 )
LCI' s 10-Year Quick Ratio Range
Min: 0.39   Max: 4.7
Current: 4.7

0.39
4.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.63
LCI's Price/Net Cash is ranked higher than
91% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 14.63 )
LCI' s 10-Year Price/Net Cash Range
Min: 17.61   Max: 28.36
Current: 14.63

17.61
28.36
Price/Net Current Asset Value 8.60
LCI's Price/Net Current Asset Value is ranked higher than
91% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 8.60 )
LCI' s 10-Year Price/Net Current Asset Value Range
Min: 4.16   Max: 93.88
Current: 8.6

4.16
93.88
Price/Tangible Book 4.88
LCI's Price/Tangible Book is ranked higher than
71% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.11 vs. LCI: 4.88 )
LCI' s 10-Year Price/Tangible Book Range
Min: 1.12   Max: 21.7
Current: 4.88

1.12
21.7
Price/DCF (Projected) 4.75
LCI's Price/DCF (Projected) is ranked higher than
78% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.36 vs. LCI: 4.75 )
LCI' s 10-Year Price/DCF (Projected) Range
Min: 0.81   Max: 5.72
Current: 4.75

0.81
5.72
Price/Median PS Value 3.22
LCI's Price/Median PS Value is ranked higher than
54% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. LCI: 3.22 )
LCI' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 6.89
Current: 3.22

0.45
6.89
Price/Peter Lynch Fair Value 1.35
LCI's Price/Peter Lynch Fair Value is ranked higher than
94% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 1.35 )
LCI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.68   Max: 1.96
Current: 1.35

0.68
1.96
Price/Graham Number 2.33
LCI's Price/Graham Number is ranked higher than
83% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.09 vs. LCI: 2.33 )
LCI' s 10-Year Price/Graham Number Range
Min: 0.94   Max: 6.23
Current: 2.33

0.94
6.23
Earnings Yield (Greenblatt) 6.70
LCI's Earnings Yield (Greenblatt) is ranked higher than
83% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. LCI: 6.70 )
LCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 14.4
Current: 6.7

0.1
14.4
Forward Rate of Return (Yacktman) 19.56
LCI's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. LCI: 19.56 )
LCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.9   Max: 88.6
Current: 19.56

-2.9
88.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:LN5.Germany
Lannett Company, Inc. was incorporated in 1942 under the laws of the Commonwealth of Pennsylvania, and reincorporated in 1991 as a Delaware corporation. The Company develops, manufactures, markets and distributes generic versions of branded pharmaceutical products. All of the products are currently manufactured and sold are prescription products. The Company's products containing Levo are produced and marketed with 12 varying potencies. In addition to generic Levo tablets, it also market and distribute Unithroid tablets, a branded version of Levo, which is produced and marketed with 11 varying potencies. Both generic Levo tablets and Unithroid tablets are manufactured by JSP. Lannett began buying generic Levo from JSP and selling it to its customers in April 2003. Levo tablets are used to treat hypothyroidism and other thyroid disorders. Levo remains the most prescribed drugs in the U.S. and is used by over 13 million patients of various ages and demographic backgrounds. In distribution of these products, the Company competes with two branded Levo products-Abbott Laboratories' Synthroid(r) and Monarch Pharmaceutical's Levoxyl(r)- as well as generic products from Mylan and Sandoz. Digoxin tablets are produced and marketed with two different potencies, 0.125mg and 0.25mg per tablet. This product is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in September 2002. Digoxin tablets are used to treat congestive heart failure in patients of various ages and demographic backgrounds. The Company distributes two products containing Butalbital. Lannett has manufactured and sold one of the products, Butalbital with Aspirin and Caffeine capsules, for more than nine years. The other Butalbital product, Butalbital with Aspirin, Caffeine and Codeine Phosphate capsules, is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in December 2002. Both Butalbital products, which are in orally administered capsule dosage forms, are prescribed to treat tension headaches caused by contractions of the muscles in the neck and shoulder area and migraine. Primidone tablets are produced and marketed with two different potencies, 50mg and 250mg tablets. Lannett has developed and manufacture Primidone tablets and began selling Primidone 50mg tablets in June 2001. In addition, the Company has been manufacturing and selling Primidone 250mg tablets for more than seven years. Both Primidone products, which are in orally administered tablet dosage forms, are prescribed to treat convulsion and seizures in epileptic patients of all ages and demographic backgrounds. Lannett sell its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities and health maintenance organizations
» More Articles for LCI

Headlines

Articles On GuruFocus.com
comment on LCI Nov 19 2012 
comment on LCI Nov 13 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 23 2012 
comment on LCI Jan 23 2012 
Lannett Company Inc Reports Operating Results (10-Q) Nov 12 2010 
Lannett Company Inc Reports Operating Results (10-K) Sep 24 2010 
View on LCI May 17 2010 
Lannett Company Inc Reports Operating Results (10-Q) May 13 2010 


More From Other Websites
LANNETT CO INC Files SEC form 8-K, Other Events Sep 18 2014
Alcobra (ADHD) Worth Watching: Stock Moves 5.1% Higher Sep 18 2014
Tetraphase Pharmaceuticals (TTPH) in Focus: Stocks Up 5.5% Sep 18 2014
Novo Nordisk's Tresiba Effective in Children & Adolescents Sep 17 2014
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Lannett Company,... Sep 17 2014
Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Filed Against Lannett Company,... Sep 16 2014
Lannett Voluntarily Conducts Internal Review in Response to Inquiry from Connecticut Attorney... Sep 16 2014
Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8% Sep 16 2014
PTC Therapeutics (PTCT) Soars: Stock Adds 11.5% is Session Sep 16 2014
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Lannett Company,... Sep 15 2014
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In... Sep 12 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Sep 12 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Sep 12 2014
EQUITY ALERT: Rosen Law Firm Reminds Lannett Company, Inc. Investors of Important Class Action... Sep 12 2014
Can Lannett Company (LCI) Run Higher on Strong Earnings Estimate Revisions? Sep 12 2014
Strength Seen in Flexion Therapeutics (FLXN): Stock Soars 17.8% Sep 11 2014
Aradigm Corporation (ARDM) Up: Stock Adds 9.7% in Session Sep 11 2014
Avanir Pharmaceuticals (AVNR) in Focus: Stock Surges 14.4% Sep 11 2014
Lannett Receives FDA Approval for Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL Sep 10 2014
Endocyte (ECYT) Worth Watching: Stock Soars 17% Sep 10 2014
Deadline in Lawsuit for Investors in Lannett Company, Inc. Shares Announced by Shareholders... Sep 09 2014
LANNETT CO INC Financials Sep 06 2014
3/27/14 Lannett to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014 Mar 27 2014
3/6/14 Lannett to Present at the 26th Annual Roth Conference on March 12 Mar 05 2014
2/6/14 Lannett Reports Fiscal 2014 2Q Financial Results Feb 06 2014
2/4/14 LLannett to Present an the 2014 Leerink Global Heathcare Conference on February 13, 2014 Feb 04 2014
1/29/14 Lannett to report Fiscal 2014 2Q Financial Restulfs on February 6, 2014 Jan 29 2014
12/19/2013 - Lannett Establishes $50 Million Revolving Credit Facility Dec 19 2013
12/03/2013 Lannett To Present At The Oppenheimer 24th Annual Healthcare Conference On December 10 Dec 03 2013
12/02/2013 -Lannett To Begin Trqding On The New York Stock Exchange Dec 02 2013
10/31/2013 - Lannett Announces Preliminary Fiscal 2014 First Quarter Net Sales of $45 Million,... Oct 31 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK